PPARG and lung carcinoma: The enhanced expression of slc10a2 triggered the expression of PPARγ, which ultimately caused an increase in PTEN expression and decrease in mTOR expression, implying that bexarotene decreases lung cancer cell survival through the slc10a2/PPARγ/PTEN/mTOR signaling pathway [249].